Syndexa is dedicated to the discovery and development of a new generation of drugs targeting novel biological mechanisms for the treatment and prevention of metabolic diseases including obesity, type 2 diabetes, and cardiovascular disease.
There is no investment information
No recent news or press coverage available for Syndexa Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
